Hospital-acquired or hospital-associated infections (HAI) or nosocomial infections are contracted from the environment or staff of a healthcare facility. It can also spread in the hospital environment, nursing home environment, rehabilitation facility, clinic, or other clinical settings. HAIs are caused by viral, bacterial, and fungal pathogens; the most common types are bloodstream infection (BSI), pneumonia (e.g., ventilator-associated pneumonia [VAP]), urinary tract infection (UTI), and surgical site infection (SSI). While antibiotic drugs to treat diseases caused by gram-positive MRSA are available, few effective drugs are available for Acinetobacter bacteria that are evolving and becoming immune to existing antibiotics. The major types of hospital infections prevalent worldwide are hospital-acquired pneumonia, urinary tract infections and surgical site infections. Hospital infections are mainly treated with antimicrobial drugs that help patients suffering from bacterial, viral or other microbial infections.
The global hospital-acquired infection therapeutics market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug type (antibacterial, antifungal and antiviral drugs), clinical pipeline analysis of phase 1, 2 and 3 drugs (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), indications (blood stream infections, gastrointestinal disorders, HAP, SSIs, UTIs, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).
The global hospital-acquired infection therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global hospital-acquired infection therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global hospital-acquired infection therapeutics market and included in this report are Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi S.A.